US FDA approves Lilly Inluriyo-Verzenio combo for ESR1-mutated metastatic breast cancer
LLY•Trial data supporting the approval
In the EMBER-3 trial, the median progression-free survival was 11.1 months for the Inluriyo-Verzenio combination versus 5.5 months for Inluriyo alone, with a hazard ratio of 0.53.
FDA approves Inluriyo-Verzenio combination
The US Food and Drug Administration granted full approval for Lilly's Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ESR1-mutated, ER+, HER2- advanced breast cancer.
The label covers patients with disease progression following at least one line of endocrine therapy, with the mutation confirmed by an FDA-authorized test.
